An experimental attention deficit hyperactivity drug developed by SuperNus Pharmaceuticals has met the main goals of two late-stage studies, bolstering the company’s case that it could provide an alternative to... Read more »
OncoMed Pharmaceuticals attracted hundreds of millions of dollars from investors and pharmaceutical partners with compounds it developed to target cells that drive cancer growth. But after a series of clinical trial... Read more »
Auris Health has already received regulatory clearance to sell its medical robot in the U.S. Now it has $220 million in funding to help it place the technology in the hands... Read more »
Roche is acquiring San Diego startup Jecure Therapeutics, with hopes of turning Jecure’s early research into a drug or drugs that treat the liver disease NASH.
Through its South San Francisco,... Read more »
Vertex Pharmaceuticals already dominates the landscape of treatments for cystic fibrosis, and its position got even better today.
Vertex (NASDAQ: VRTX) said that a cocktail of three of its cystic... Read more »
The FDA has ordered Zafgen to suspend a mid-stage study testing its experimental diabetes drug, an apparent precautionary move.
A clinical hold halts patient enrollment and also stops already enrolled patients... Read more »
PellePharm now has a partner to finance late-stage clinical tests of its experimental treatment for a rare skin cancer that has no FDA-approved drug treatment.
Denmark-based LEO Pharma has agreed to... Read more »
The food we buy in grocery stores and restaurants has a story to tell about where it came from and each step it took on its journey to your dinner table.... Read more »
We’ll soon find out if Wall Street has the appetite for investing in alternative meat technology.
Beyond Meat, a maker of plant-based meat products, has filed for an IPO. The El... Read more »
Thanksgiving is around the corner and this week delivered a bounty of deals that have a number of life science companies expressing their thanks a little early.
One deal saw a... Read more »
[Updated, 11/15/18, 2:06 p.m. ET. See below.] Arena Pharmaceuticals continued its comeback Thursday, netting a whopping $800 million up front in a deal that hands United Therapeutics another experimental... Read more »
The shaking, tremors, and loss of muscle control in some movement disorders can be traced to misfiring neurons. Cadent Therapeutics has developed a drug intended to help those neurons send signals... Read more »
Celgene’s collaboration with Dragonfly Therapeutics is less than 18 months old, but the pharmaceutical company is already expanding the alliance.
Celgene (NASDAQ: CELG) is paying Waltham, MA-based Dragonfly $50 million... Read more »
Cells have a built-in way of breaking down damaged or unneeded proteins. Kymera Therapeutics is trying to harness this process as a therapy—using it to get rid of disease-causing proteins. As... Read more »
Each new technology has a story behind it. On Dec. 5, our Xchange Forum will offer a behind-the-scenes look at how some of them aim to transform healthcare.
Xconomy’s San Francisco... Read more »
Treatments for patients who have atrial fibrillation (AF), an irregular heartbeat, include pills that take time to work, or hospital-based procedures. InCarda Therapeutics aims to offer an alternative: a fast-acting inhalable... Read more »
A product that reduces emissions from farm animal waste? There’s now a drug for that.
The FDA has approved an Elanco (NYSE: ELAN) drug developed to reduce the ammonia gas... Read more »
Eli Lilly hasn’t been shy about making deals to build up its cancer immunotherapy pipeline, and its latest one is with NextCure, a biotech with technology that finds molecular targets to... Read more »
For the second time in three years, Amgen is turning to a smaller biotech to continue clinical development of an experimental celiac disease drug that was developed in its labs.
Under... Read more »
[Updated, 11/2/18, 11:09 a.m. ET. See below.] DNA sequencing giant Illumina is shoring up its position in genetic research through a cash deal to acquire Pacific Biosciences for approximately... Read more »